Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

22nd Century Group Inc's Subsidiary Enters Into Research License and Commercial Option Agreement with British American Tobacco PLC's Subsidiary-Form 8-K


Tuesday, 1 Oct 2013 05:09pm EDT 

22nd Century Group Inc reported in its Form 8-K on October 1, 2013, 22nd Century Limited, LLC (Company), a wholly-owned subsidiary of 22nd Century Group, Inc., entered into a Research License and Commercial Option Agreement with British American Tobacco (Investments) Limited (BAT), a subsidiary of British American Tobacco plc. The Registrant executed the Research Agreement for the sole purpose of guaranteeing the obligations of the Company under the Research Agreement. Under the terms of the Research Agreement, BAT receives an exclusive worldwide license to certain patent rights for a period of up to four years. During the four year term of the Research Agreement, BAT also has an option to obtain an exclusive worldwide license to commercialize certain products derived from utilizing the patent rights and licensed intellectual property rights under the terms of a Commercial License Agreement, the form of which is attached to the Research Agreement. BAT and the Company also agreed to collaborate with each other as each party engages in its own independent research during the term of the Research Agreement. BAT also granted to the Company a worldwide license to any and all registered research results developed and owned by BAT which results or arises from any research, development or other activities of BAT under the Research Agreement. 

Company Quote

3536.0
-21.0 -0.59%
11:03am EDT